ACUT
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.03 | $0 | -$374,176 |
| 2025 Q4 | -0.04 | $0 | $22,357 |
| 2025 Q3 | -0.02 | $0 | -$604,131 |
| 2025 Q2 | -0.03 | $0 | -$269,029 |
| 2025 Q1 | -0.03 | $0 | -$290,182 |
| 2024 Q4 | -0.03 | $3,630 | $414 |
| 2024 Q3 | -0.03 | $0 | -$217,949 |
| 2024 Q2 | -0.02 | $0 | -$209,180 |